Results 51 to 60 of about 13,707 (310)

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5 [PDF]

, 2022
Background: Mepolizumab, an anti-interleukin-5 (IL-5) antibody, reduces disease flares in patients with hypereosinophilic syndrome (HES). Factors predicting treatment response are unknown.
Akuthota P., Alonso A., Antila M. A., Blanco D., Blockmans D., Brockow K., Butterfield J. H., Cerino-Javier R., Chupp G. L., Cid Xutgla M. C., Cox J. B., Delgado R. G., Faguer S., Fox M. L., Francisco Pez A. L., Garcia G. R., Gazca-Aguilar A., Gleich G. J., Gonzalez A. I., Grava S., Gritsaev S. V., Hamidou M. A., Hernandez Rivas J. M., Hernandez-Colin D. D., Ivanov V., Jhaveri D., Kahn J. -E., Kern P. M., Kuprys-Lipinska I. R., Kwon N., Lefevre G., Lima M. A., Mavropoulou E., Mihaly E., Musial J., Pane F., Popov V., Prejzner W., Reiter A. J., Rothenberg M. E., Roufosse F., Santillana G. S., Sosso A., Steinfeld J., Tsyba N., Valdez-Lopez H. G., Vannucchi A. M., Walz B., Wardlaw A. J., Wehbe L., Welte T., Yancey S. W., Yanez A., Zdrenghea M. T.   +53 more
core   +1 more source

Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacy

International Forum of Allergy and Rhinology, 2023
The heterogeneity of existing studies, along with the fact that there are no published head‐to‐head trials, are the main reasons for the lack of guidelines regarding the selection of the proper biologic in treatment of chronic rhinosinusitis (CRS) with ...
Georgios X Papacharalampous, J. Constantinidis, G. Fotiadis, N. Zhang, C. Bachert, M. Katotomichelakis   +5 more
semanticscholar   +1 more source

The Role of ACT Score in Mepolizumab Discontinuation

Journal of Asthma, 2023
AbstractBackgroundMepolizumab is a therapy for severe asthma. However, studies on mepolizumab with external validity and diverse population from the US are lacking. There is little knowledge of the characteristics of people that discontinue mepolizumab in clinical care.ObjectiveTo investigate the real-world efficacy and time to clinical discontinuation
Neha Solanki, Brittany Beck, Monica Labadia, Kevin Smith, Laura Peterson, Stephanie King, Sarah Micklewright, Emily Pennington, Sobia Farooq, Peng Zhang, Mark Aronica, Joe Zein, Sumita Khatri, Suzy Comhair, Serpil Erzurum   +14 more
openaire   +2 more sources

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis [PDF]

New England Journal of Medicine, 2017
Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis. Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment of eosinophilic granulomatosis with polyangiitis.In this multicenter, double-blind, parallel-group, phase 3 trial, we randomly assigned participants with
Wechsler, Michael E, Akuthota, Praveen, Jayne, David, Khoury, Paneez, Klion, Amy, Langford, Carol A, Merkel, Peter A, Moosig, Frank, Specks, Ulrich, Cid, Maria C, Luqmani, Raashid, Brown, Judith, Mallett, Stephen, Philipson, Richard, Yancey, Steve W, Steinfeld, Jonathan, Weller, Peter F, Gleich, Gerald J, Chiara Baldini, Douglas M Beach, Bruce Bochner, Arnaud Bourdin, Pascal Chanez, Anoop Chauhan, Vincent Cottin, Joshua Denson, Yeshai Dollin, Ryan M Dunn, Bertrand Dunogue, Georgina Espígol-Frigolé, Aryeh Fischer, Rula Hajj-Ali, Berhnard Hellmich, José Hernández-Rodríguez, Julia Holle, Christof Iking-Konert, Tomonori Ishii, Jean-Emmanuel Kahn, Peter Kern, Nader Khalidi, Curry L Koening, Andrea Matucci, Paul Monach, Lindsay Morehouse, Ryann Murphy, Thomas Neumann, Christian Pagnoux, Elide Pastorello, Sergio Prieto-González, Xavier Puechal, Benjamin A Raby, Florence Roufosse, Maria Grazia Sabbadini, Jan Schirmer, Antoine G Sreih, Masami Taniguchi, Reinhard Voll, Andrew Wardlaw   +58 more
openaire   +5 more sources

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,, BEGHE', Bianca, Fabbri, Lm3, Papi, A1   +3 more
core   +1 more source

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma [PDF]

New England Journal of Medicine, 2009
Exacerbations of asthma are associated with substantial morbidity and mortality and with considerable use of health care resources. Preventing exacerbations remains an important goal of therapy. There is evidence that eosinophilic inflammation of the airway is associated with the risk of exacerbations.We conducted a randomized, double-blind, placebo ...
Haldar, P, Brightling, CE, Hargadon, B, Gupta, S, Monteiro, W, Sousa, A, Marshall, RP, Bradding, P, Green, RH, Wardlaw, AJ, Pavord, ID   +10 more
openaire   +4 more sources

Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis [PDF]

, 2019
Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a therapeutic challenge because of the high recurrence rate. Surgical intervention should be considered in patients who fail to improve after medical treatment.
Bachert, Claus, Bosteels, Cedric, CALUS, LIEN, Dejonckheere, Sarah, Gevaert, Philippe, Holtappels, Gabriële, VAN BRUAENE, NICHOLAS, Van Zele, Thibaut   +7 more
core   +1 more source

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Frontiers in Medicine, 2023
BackgroundHypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage.
Florence Roufosse, Joseph Butterfield, Jonathan Steinfeld, Jane H. Bentley, Robyn von Maltzahn, Namhee Kwon, Linda Nelsen   +6 more
doaj   +1 more source

Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study [PDF]

, 2021
Background: A double-blind, placebo-controlled, phase III study (200622) showed that mepolizumab reduces disease flares for patients with uncontrolled FIP1-like-1-platelet-derived growth factor receptor α–negative hypereosinophilic syndrome (HES) and two
Akuthota P., Antila M. A., Bentley J. H., Blanco D., Blockmans D., Butterfield J. H., Cerino-Javier R., Chupp G., Chupp G. L., Cid M. C., Faguer S., Fox M. L., Francisco Pez A. L., Garcia G. R., Gleich G. J., Hernandez-Colin D. D., Ivanov V., Jhaveri D., Kahn J. -E., Kern P. M., Kuprys-Lipinska I. R., Lefevre G., Mihaly E., Musial J., Neel A., Pane F., Pascale P., Popov V. M., Reiter A., Reiter A. J., Rothenberg M. E., Roufosse F., Santillana G. S., Steinfeld J., Tsyba N., Valdez-Lopez H. G., Vannucchi A. M., Walz B., Wardlaw A. J., Wehbe L., Welte T., Yancey S. W.   +41 more
core   +1 more source

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

Health Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj